Patterns of Temporal Lobe Reaction and Radiation Necrosis after Particle Radiotherapy in Patients with Skull Base Chordoma and Chondrosarcoma-A Single-Center Experience.

carbon ion chondrosarcoma chordoma heavy ion necrosis proton radiotherapy skull base

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
08 Feb 2024
Historique:
received: 28 12 2023
revised: 01 02 2024
accepted: 02 02 2024
medline: 24 2 2024
pubmed: 24 2 2024
entrez: 24 2 2024
Statut: epublish

Résumé

The current study aims to evaluate the occurrence of temporal lobe reactions and identify possible risk factors for patients who underwent particle therapy of the skull base. 244 patients treated for skull base chordoma ( 51 patients with chordoma (35.4%) and 30 patients (30%) with chondrosarcoma experienced at least one temporal lobe reaction within the follow-up period (median 49 months for chondrosarcoma, 62 months for chordoma). Age, irradiated volume, and dose values were significant risk factors for the development of temporal lobe reactions with the highest significance for the value of DMax-7 being defined as the dose maximum in the temporal lobe minus the 7cc with the highest dose ( Temporal lobe reactions are a common side effect after particle therapy of the skull base. We were able to develop a multivariate model, which predicted radiation reactions with a specificity of 99% and a sensitivity of 52.2%.

Sections du résumé

BACKGROUND BACKGROUND
The current study aims to evaluate the occurrence of temporal lobe reactions and identify possible risk factors for patients who underwent particle therapy of the skull base.
METHODS METHODS
244 patients treated for skull base chordoma (
RESULTS RESULTS
51 patients with chordoma (35.4%) and 30 patients (30%) with chondrosarcoma experienced at least one temporal lobe reaction within the follow-up period (median 49 months for chondrosarcoma, 62 months for chordoma). Age, irradiated volume, and dose values were significant risk factors for the development of temporal lobe reactions with the highest significance for the value of DMax-7 being defined as the dose maximum in the temporal lobe minus the 7cc with the highest dose (
CONCLUSION CONCLUSIONS
Temporal lobe reactions are a common side effect after particle therapy of the skull base. We were able to develop a multivariate model, which predicted radiation reactions with a specificity of 99% and a sensitivity of 52.2%.

Identifiants

pubmed: 38398109
pii: cancers16040718
doi: 10.3390/cancers16040718
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Matthias Mattke (M)

Department of Radiation Oncology, Paracelsus Medical University, Salzburger Landesklinikum (SALK), 5020 Salzburg, Austria.
Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.

Matteo Ohlinger (M)

Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.

Nina Bougatf (N)

Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Robert Wolf (R)

Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.

Thomas Welzel (T)

Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.

Falk Roeder (F)

Department of Radiation Oncology, Paracelsus Medical University, Salzburger Landesklinikum (SALK), 5020 Salzburg, Austria.
Institute of Research and Development of Advanced Radiation Technologies (radART), Paracelsus Medical University, 5020 Salzburg, Austria.

Sabine Gerum (S)

Department of Radiation Oncology, Paracelsus Medical University, Salzburger Landesklinikum (SALK), 5020 Salzburg, Austria.

Christoph Fussl (C)

Department of Radiation Oncology, Paracelsus Medical University, Salzburger Landesklinikum (SALK), 5020 Salzburg, Austria.

Natalee Annon-Eberharter (N)

Department of Radiation Oncology, Paracelsus Medical University, Salzburger Landesklinikum (SALK), 5020 Salzburg, Austria.

Malte Ellerbrock (M)

Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Oliver Jäkel (O)

Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Division for Medical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Thomas Haberer (T)

Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Klaus Herfarth (K)

Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Matthias Uhl (M)

Department of Radiation Oncology, Ludwigshafen Hospital, 67063 Ludwigshafen, Germany.

Jürgen Debus (J)

Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany.
German Cancer Consortium (DKTK), Partner Site Heidelberg, 69120 Heidelberg, Germany.

Katharina Seidensaal (K)

Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.

Semi Harrabi (S)

Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.

Classifications MeSH